Abivax SA
PAR:ABVX
Abivax SA
Total Liabilities
Abivax SA
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Total Liabilities
€168m
|
CAGR 3-Years
32%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities
€297.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
9%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities
€164.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
29%
|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities
€187.9m
|
CAGR 3-Years
69%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Liabilities
$57.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
16%
|
|
|
Sensorion SA
PAR:ALSEN
|
Total Liabilities
€16.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Total Liabilities?
Total Liabilities
168m
EUR
Based on the financial report for Jun 30, 2025, Abivax SA's Total Liabilities amounts to 168m EUR.
What is Abivax SA's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
26%
Over the last year, the Total Liabilities growth was 6%. The average annual Total Liabilities growth rates for Abivax SA have been 32% over the past three years , 26% over the past five years .
